Kiadis Pharma pro­pos­es for­mer Cipla CEO Subhanu Saxena as new Supervisory Board mem­ber

Amsterdam-Duivendrecht, The Netherlands, January 16, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell ther­a­py prod­ucts to make bone mar­row trans­plan­ta­tions safer and more effec­tive for patients, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nom­i­nate Subhanu Saxena to be appoint­ed as a new mem­ber of the Supervisory Board.
Subhanu Saxena is cur­rent­ly a Regional Director with The Bill & Melinda Gates Foundation as well as part­ner New Rhein Healthcare and Senior Advisor to Bain Capital. He was, until recent­ly, the Managing Director and Global Chief Executive Officer of Cipla, a pub­licly list­ed, lead­ing Indian phar­ma­ceu­ti­cal and biotech com­pa­ny with glob­al oper­a­tions and around 25,000 employ­ees. During Mr. Saxena’s lead­er­ship Cipla was trans­formed into a more inter­na­tion­al and agile com­pa­ny. Prior to join­ing Cipla, Mr. Saxena was Head of Global Product Strategy and Commercialization and mem­ber of the Executive Committee at Novartis. Before that, Mr. Saxena was CEO of Novartis UK and held var­i­ous lead­er­ship roles in busi­ness devel­op­ment. Prior to join­ing the phar­ma indus­try Mr. Saxena worked with lead­ing glob­al com­pa­nies includ­ing Citicorp, the Boston Consulting Group and PepsiCo across mar­kets in Europe, North America, Africa and Asia. Mr. Saxena holds a Graduate degree in Engineering from Oxford University and an MBA from INSEAD, France.

Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “I am delight­ed Subhanu has decid­ed to join our Supervisory Board. As we con­tin­ue to pro­fes­sion­al­ize our com­pa­ny and pre­pare for the poten­tial European com­mer­cial launch of ATIR101™ in H2 2019, Subhanu’s vast lead­er­ship expe­ri­ence in build­ing and trans­form­ing a wide vari­ety of orga­ni­za­tions will be of immense val­ue for Kiadis Pharma and help us tremen­dous­ly to make ATIR101™ wide­ly avail­able to patients.’’

Subhanu Saxena added: “I am very pleased to join the Kiadis Pharma Supervisory Board and am impressed by the Company’s inves­ti­ga­tion­al prod­uct and tech­nol­o­gy plat­form, which I am con­vinced can serve patients with a safer and more effec­tive bone mar­row trans­plan­ta­tion. I look for­ward to sup­port the fur­ther matur­ing of Kiadis Pharma.’’

Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma, com­ment­ed: “We are very hap­py to wel­come Subhanu to our Supervisory Board. His wealth of glob­al strate­gic and com­mer­cial expe­ri­ence will be invalu­able to Kiadis Pharma in the next stages of its growth and con­tin­ued trans­for­ma­tion into a suc­cess­ful com­mer­cial stage com­pa­ny.